» Articles » PMID: 24647014

HIV-1 DNA Levels in Peripheral Blood Mononuclear Cells and Cannabis Use Are Associated with Intermittent HIV Shedding in Semen of Men Who Have Sex with Men on Successful Antiretroviral Regimens

Abstract

Background: Few data exist on the efficacy of combined antiretroviral therapy (cART) in semen of human immunodeficiency virus type 1 (HIV-1) infected men who have sex with men (MSM) with sustained control of HIV replication in blood.

Methods: HIV-1 infected MSM on successful cART for >6 months were enrolled. HIV-RNA was quantified in seminal plasma (spVL) and in blood plasma (bpVL) from 2 paired samples collected 4 weeks apart. Relationship between spVL and bpVL (measured by an ultrasensitive assay, LOQ 10 copies/mL), total peripheral blood mononuclear cells (PBMC)-associated HIV-DNA, sexually transmitted infections (STIs), and self-reported socio-behavioral characteristics was assessed using GEE logistic regression.

Results: In total, 157 patients were included. Median time with bpVL <50 copies/mL was 3.3 years. spVL was detectable in 23/304 samples (prevalence 7.6%). Median spVL was 145 cp/mL (100-1475). spVL was detectable on the first, on the second, and on both samples in 5, 14, and 2 men, respectively. In sum, 33 individuals (21%) had STIs (asymptomatic in 24/33). Residual bpVL was undetectable by ultrasensitive assay in 225/300 samples (75%). After multivariable adjustments, PBMC-associated HIV-DNA (OR 2.6[1.2; 6.0], for HIV-DNA > 2.5 log10 cp/10(6) PBMC, P = .02), and cannabis use during sexual intercourse (OR 2.8[1.2; 6.7], P = .02) were the only factors associated significantly with spVL.

Conclusion: We show that HIV-RNA can be detected intermittently in semen of HIV-1 infected MSM despite successful cART. The size of blood HIV-1 reservoir predicted spVL detection. Our results indicated also that the possible effect of cannabis should be taken into account when developing prevention interventions targeted toward HIV-infected MSM on successful cART.

Citing Articles

Impact of Cannabis Use on Immune Cell Populations and the Viral Reservoir in People With HIV on Suppressive Antiretroviral Therapy.

Falcinelli S, Cooper-Volkheimer A, Semenova L, Wu E, Richardson A, Ashokkumar M J Infect Dis. 2023; 228(11):1600-1609.

PMID: 37606598 PMC: 10681869. DOI: 10.1093/infdis/jiad364.


Effects of Oral Cannabinoids on Systemic Inflammation and Viral Reservoir Markers in People with HIV on Antiretroviral Therapy: Results of the CTN PT028 Pilot Clinical Trial.

Mboumba Bouassa R, Comeau E, Alexandrova Y, Pagliuzza A, Yero A, Samarani S Cells. 2023; 12(14).

PMID: 37508476 PMC: 10378564. DOI: 10.3390/cells12141811.


Confound, Cause, or Cure: The Effect of Cannabinoids on HIV-Associated Neurological Sequelae.

Starr A, Jordan-Sciutto K, Mironets E Viruses. 2021; 13(7).

PMID: 34206839 PMC: 8310358. DOI: 10.3390/v13071242.


Mini-review: The therapeutic role of cannabinoids in neuroHIV.

Yadav-Samudrala B, Fitting S Neurosci Lett. 2021; 750:135717.

PMID: 33587986 PMC: 7994193. DOI: 10.1016/j.neulet.2021.135717.


Medical Marijuana and Opioids (MEMO) Study: protocol of a longitudinal cohort study to examine if medical cannabis reduces opioid use among adults with chronic pain.

Cunningham C, Starrels J, Zhang C, Bachhuber M, Sohler N, Levin F BMJ Open. 2020; 10(12):e043400.

PMID: 33376181 PMC: 7778768. DOI: 10.1136/bmjopen-2020-043400.